British Thoracic Oncology Group (BTOG) - multi-disciplinary group for professionals involved with thoracic malignancies.
Joined August 2014
- Tweets 8,033
- Following 428
- Followers 4,169
- Likes 2,557
1,604 Photos and videos
TNM9 is now being implemented in lung cancer MDTs.
In the latest BTOG webcast, @LungConsultant is joined by Dr Tanya Patrick to explain what has changed, including N2A/N2B, M1C1/M1C2 and the practical implications for staging pathways.
Watch/listen to the full episode on our website btog.org/btog-podcasts/ or Apple Podcasts, Spotify, Amazon Music or YouTube #LungCancer #LCSM
1
1
85
The treatment landscape for EGFR-mutant NSCLC has entered an exciting but complex era. For #ASCODailyNews, @guicorreiamd, @VamsiVelcheti, and Varun Elete discuss 3 valuable first-line approaches and the use of #ctDNA clearance to adapt therapy: bit.ly/43w4DYV
1
4
4
2,232
BTOG retweeted
Jun 10
🫁 Can early ctDNA help predict survival in NSCLC treated with radiotherapy?
A new Clinical Cancer Research study suggests that it can.
Hashmi and colleagues evaluated ctFE, circulating tumor fraction estimate a machine learning-derived metric of ctDNA burden in plasma.
The study focused on patients with locally advanced and oligometastatic NSCLC treated with radiotherapy-based approaches.
Key findings:
🧬 Baseline ctFE strongly stratified survival
📌 OS: HR 5.93; P = 0.005
📌 PFS: HR 11.08; P < 0.001
⏱️ Mid-treatment ctFE, measured during days 10–14, remained highly prognostic
📌 OS: HR 7.08
📌 PFS: HR 12.06
📌 Both P < 0.001
ctFE also outperformed Max VAF and simple ctDNA detectability.
Most strikingly, early ctFE dynamics defined 3 molecular response groups with very different median overall survival:
✅ Favorable response: 60.8 months
⚠️ Intermediate response: 13.0 months
🔴 Poor response: 2.9 months
📌 P < 0.001
The biomarker was also validated in two external cohorts:
🏥 Locally advanced NSCLC treated with chemoRT: n = 94
🏥 Oligometastatic NSCLC treated with RT: n = 309
The takeaway:
Early ctDNA burden may provide a practical, noninvasive way to identify high-risk patients during treatment, before conventional imaging can fully define response.
This could support more personalized treatment adaptation in locally advanced and oligometastatic NSCLC.
Reference: Hashmi et al., Clinical Cancer Research, 2026.
@kaushalpar @MalvikaPillai @JPatelMD @semenko @AMansfieldMD @SBRT_CR @BrunaPellini @aadel_chaudhuri
1
8
18
968
"First time to be in an international conference. Totally worth the time. Everything is perfect and well-organised."
Feedback from our Annual Conference 2026. You can read the recap and see photos and short videos on our website btog.org/2026-annual-confere…
1
1
96
BTOG retweeted
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies.
Read the full article. bit.ly/4v1vY19
#LungCancer #lcsm
4
5
1,219
BTOG retweeted
Mar 2
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-7…
1
63
159
15,974
BTOG retweeted
Today marks 22 years since EGFR mutations were discovered in #lungcancer - a discovery that changed everything.
From first TKIs to osimertinib, adjuvant therapy and beyond. More people are living longer. Research into resistance is accelerating.
Still a long way to go - but 22 years of progress is worth marking. 💜
#LCSM
4
10
142
Can we move the needle in LCNEC? Is MRD-based treatment in NSCLC ready for prime time?
Join leading UK experts at the BTOG National Trials Meeting 2026.
📅 22 July | London
Free registration for eligible oncology professionals:
btog.org/btog-trials-meeting…
@DrSanjayPopat @tnewsomdavis @caliraf @Anna_Minchom @fblackhall @AlastairGreyst2 @ClinOncologist @OncoloJo
2
5
259
Your experience as a BTOG member is important to us.
Share your thoughts in our 2026 survey.
👉 btog.org/btog-membership-sur…
56
BTOG retweeted
Jun 9
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
ja.ma/4oh4KRG
ALT Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
12
28
2,558
BTOG retweeted
Looking for the latest insights from the National Lung Cancer Audit? 🎧
Tune into the new @BTOGORG podcast discussing audit findings, improvement activity and the recently published State of the Nation Report ow.ly/coLX50Z6GAw
1
1
54
BTOG retweeted
Jun 8
One week left to register❗
The ERS Academy of adult respiratory medicine will cover major fields of respiratory medicine, including respiratory failure, smoking cessation, respiratory infections, and more.
Register now: channel.ersnet.org/media-121…
1
352
📣 The Residents' Corner paper on ‘Why should the current generation of surgical residents be academically active — lessons from the past’ is now live!
This latest paper explores why academic engagement matters in cardiac surgery and why today’s residents must go beyond technical excellence to help shape the evidence that defines future practice. For the next generation of surgeons, being technically skilled is only part of the story; staying academically active, data-literate, and engaged in research is equally important.
📖 Read the full paper ⛓️💥 doi.org/10.1093/ejcts/ezag11…
1
7
597
BTOG retweeted
Uncommon EGFR mutations are heterogeneous alterations. Specific mutations may respond differently to EGFR-TKIs, highlighting the importance of molecular profiling to identify unique alterations and guide treatment decisions.
Check out this recent article: bit.ly/4vBfRaE
8
27
1,948
BTOG retweeted
Jun 6
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
ja.ma/4fqf0ER
ALT Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
3
14
29
2,713
BTOG retweeted
Important data.
‼️ Landmark #lungcancer research published today in Cell
Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment.
People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half.
This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk.
doi.org/10.1016/j.cell.2026.…
#LCSM
11
27
3,942
Go home and look at your data!
“We can only improve services if we know what we do well and what we maybe do less well.”
Watch or listen now 🎧
btog.org/btog-nlca-webinar-s…
@NLCA_uk
1
119
"I really enjoyed the conference and the networking and the ability to debate and discuss with colleagues. This was clearly a high quality conference with much to be proud of. Thank you."
btog.org/2026-annual-confere…
Save the dates for our 25th Annual Conference in 2027: Wednesday 3rd March to Friday 5th March. EICC, Edinburgh.
1
1
209
Our new living guideline Therapy for Stage IV NSCLC With Driver Alterations emphasizes broad NGS & IHC (PD-L1, HER2, MET) prior to frontline therapy. Comprehensive profiling is linked to ⬆️ OS & cost-effectiveness in Stage IV NSCLC: bit.ly/4wHjjSf
#LungCancer #NSCLC
7
18
6,010
From conferences to webinars—your feedback helps shape it all.
Complete the BTOG 2026 Membership Survey today.
👉 btog.org/btog-membership-sur…
1
108